Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Top Cited Papers
- 13 September 2018
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 379 (11), 1007-1016
- https://doi.org/10.1056/nejmoa1805689
Abstract
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or variant transthyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing tetramer dissociation and amyloidogenesis.Keywords
Funding Information
- Pfizer, Inc.
This publication has 33 references indexed in Scilit:
- Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacementEuropean Heart Journal, 2017
- Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac ImagingJAMA Cardiology, 2016
- Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging SystemJournal of the American College of Cardiology, 2016
- Genotype and Phenotype of Transthyretin Cardiac AmyloidosisJournal of the American College of Cardiology, 2016
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCirculation, 2016
- Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thicknessEuropean Heart Journal, 2015
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEuropean Heart Journal, 2015
- Transthyretin (TTR) Cardiac AmyloidosisCirculation, 2012
- Transthyretin-related amyloidoses and the heart: a clinical overviewNature Reviews Cardiology, 2010
- Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 ÅJournal of Molecular Biology, 1978